Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update

Rhea-AI Summary

Aadi Bioscience, a precision oncology company, will report its Q1 2024 results and provide corporate updates on May 8, 2024. The company focuses on developing therapies for cancers with alterations in the mTOR pathway. A conference call and webcast will be held, allowing participants to access the call through the company's website or via telephone registration. A replay will be available for 30 days.

Company to Host Conference Call and Webcast on May 8, 2024

LOS ANGELES, May 1, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024 at 8:30 am EDT (5:30 am PDT) to report first quarter 2024 financial results and provide recent corporate updates.

Conference Call Information 

Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com. To participate via telephone, please register in advance here: Conference Registration (vevent.com). Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the website for at least 30 days.

About Aadi Bioscience, Inc.

Aadi is a commercial-stage precision oncology company focused on the development and commercialization of therapies for cancers with alterations in the mTOR pathway, a key regulator of cell growth and cancer progression. To unlock the full potential of mTOR inhibition, Aadi uniquely combines nanoparticle albumin-bound (nab) technology with the potent mTOR inhibitor, sirolimus. Aadi received FDA approval and commercializes FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Aadi is exploring nab-sirolimus in PRECISION1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. Aadi is also exploring nab-sirolimus in two single-indication Phase 2 trials for difficult-to-treat mTOR-driven cancers: neuroendocrine tumors (NETs), and advanced or recurrent endometrioid-type endometrial cancer (EEC) in combination with letrozole. More information on the Company's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Contact:
IR@aadibio.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-report-first-quarter-2024-results-and-corporate-update-302132110.html

SOURCE Aadi Bioscience

FAQ

When will Aadi Bioscience report its Q1 2024 results?

Aadi Bioscience will report its Q1 2024 results on May 8, 2024.

What is the focus of Aadi Bioscience in terms of therapy development?

Aadi Bioscience focuses on developing therapies for cancers with alterations in the mTOR pathway.

How can participants access the conference call and webcast?

Participants can access the call through the Aadi Bioscience website or via telephone registration.

Will there be a replay available for the conference call and webcast?

Yes, a replay of the conference call and webcast will be archived on the website for at least 30 days.